ITGAM and neoplasm: We also observed that responders had increased percentages of splenic KLRG1+ mature NK cells and tumor-infiltrating CD11b-/CD27- immature NK cells, and decreased percentages of tumor-infiltrating CD11b+/CD27-activated NK cells two weeks after treatment initiation (Figure 4F,G).